Submission of a variation to EMA for the vaccination of children 6 months to less than 5 years with Comirnaty.
Pfizer Inc. and BioNTech SE announced that the companies have submitted a variation to the European Medicines Agency (EMA) requesting to update the Conditional Marketing Authorization (CMA) in the European Union (EU) with data supporting the vaccination of children ages 6 months to less than 5 years with the 3-µg dose of Comirnaty (COVID-19 vaccine, mRNA) as a three dose series.
The 3-µg dose was carefully selected as the preferred dose for children less than 5 years of age based on safety, tolerability, and immunogenicity data.
The submission included data from a Phase II/III randomized, controlled trial that included 4,526 children 6 months to less than 5 years of age. In the trial, children received the third 3-µg dose at least two months after the second dose at a time when Omicron was the predominant variant. Following a third dose in this age group, the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. No new safety signals were identified, and the frequency of adverse reactions observed in children 6 months to less than 5 years were generally lower than in children 5 to less than 12 years.
Related news and insights
Roche announced that the FDA has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations, as detected by a FDA-approved test, and who have received a prior systemic therapy
Agios Pharmaceuticals, Inc. announced that data from the core period of the open-label, Phase II study of Pyrukynd (mitapivat) in adults with non-transfusion-dependent alfa- or beta-thalassemia were published on August 11, 2022, in The Lancet